Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
Children With and Without Allergic Asthma Experience Less Exacerbation After Receiving Dupilumab.
Read Full NewsModelling shows fewer cases and deaths with screening starting at age 45 years.
A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.
Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.
1.
A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.
2.
An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.
3.
Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma
4.
Cancer and HIV Vaccines Enter the Therapeutic Era
5.
Prior authorizations draining time, energy from many cancer patients
1.
Intrapancreatic Fat, Pancreatitis, and Cancer: Role of Cancer-Associated Fibroblasts
2.
Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound
3.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
4.
Evolution of Cancer Care Through Developmental Therapeutics
5.
What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge